英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字,中文词皆可:

coherence    音标拼音: [koh'ɪrəns]
n. 附着,粘着,凝聚,一致性

附着,粘着,凝聚,一致性

coherence
n 1: the state of cohering or sticking together [synonym:
{coherence}, {coherency}, {cohesion}, {cohesiveness}] [ant:
{incoherence}, {incoherency}]
2: logical and orderly and consistent relation of parts [synonym:
{coherence}, {coherency}]

Coherence \Co*her"ence\, Coherency \Co*her"en*cy\, n. [L.
cohaerentia: cf. F. coh['e]rence.]
1. A sticking or cleaving together; union of parts of the
same body; cohesion.
[1913 Webster]

2. Connection or dependence, proceeding from the
subordination of the parts of a thing to one principle or
purpose, as in the parts of a discourse, or of a system of
philosophy; a logical and orderly and consistent relation
of parts; consecutiveness.
[1913 Webster]

Coherence of discourse, and a direct tendency of all
the parts of it to the argument in hand, are most
eminently to be found in him. --Locke.
[1913 Webster]

3. the state of cohering.

Syn: cohesion, cohesiveness.
[WordNet 1.5]

103 Moby Thesaurus words for "coherence":
accord, accordance, accretion, adherence, adhesion, affinity,
agglomeration, agglutination, agreement, assent, bond, chorus,
clarity, clear-cutness, clearness, cling, clinging, clotting,
clustering, coagulation, cohesion, cohesiveness, coincidence,
compaction, compatibility, concert, concord, concordance,
concretion, condensation, conformance, conformation, conformity,
congealment, congelation, congeniality, conglobation,
conglomeration, congruence, congruency, congruity, connectedness,
consistency, consolidation, consonance, consort, cooperation,
correspondence, crystallinity, definition, directness,
distinctness, equivalence, explicitness, harmony, impartibility,
indiscerptibility, indissolubility, indivisibility, infrangibility,
infusibility, inseparability, insolubility, integrity,
intersection, junction, limpidity, lucidity, oneness, overlap,
parallelism, peace, pellucidity, perspicuity, plain English,
plain speech, plain style, plainness, rapport, self-consistency,
set, simplicity, solidarity, solidification, sticking,
straightforwardness, structure, symmetry, sync, synchronism, tally,
timing, transparency, transpicuity, unadorned style,
unambiguousness, unequivocalness, uniformity, union, unison,
unisonance, unity, unmistakableness


请选择你想看的字典辞典:
单词字典翻译
Coherence查看 Coherence 在百度字典中的解释百度英翻中〔查看〕
Coherence查看 Coherence 在Google字典中的解释Google英翻中〔查看〕
Coherence查看 Coherence 在Yahoo字典中的解释Yahoo英翻中〔查看〕





安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate . . .
    Lutetium-177 (177 Lu)–PSMA-617 is a radioligand therapy that delivers beta-particle radiation to PSMA-expressing cells and the surrounding microenvironment Methods
  • 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant . . .
    Waterfall plots of A PSA responses (percentage change from baseline value) after the first 177 Lu-PSMA-617 cycle and B best PSA responses to the overall course of 177 Lu-PSMA-617 RLT for the entire cohort (N = 254) PD, [biochemical] progressive disease; PR, [biochemical] partial response; RLT, radioligand therapy; SD, [biochemical] stable disease
  • Novartis Pluvicto™ approved by FDA as first targeted radioligand . . .
    Novartis is committed to reimagining medicine in prostate cancer with targeted radioligand therapy - a type of precision cancer treatment combining a targeting compound (ligand) with a therapeutic radioisotope (a radioactive particle) (lutetium Lu 177 vipivotide tetraxetan) (formerly referred to as 177 Lu-PSMA-617) for the treatment of
  • Pluvicto (177Lu-PSMA-617): Uses in Cancer, Side Effects, Dosage . . .
    The CATCH-177 study (NCT06738303) compares Carboplatin and Cabazitaxel with 177Lu-PSMA-617 in metastatic castrate-resistant prostate cancer (mCRPC) that is resistant to hormone therapy and docetaxel The goal is to identify the most effective treatment and optimal sequencing for patients with this aggressive form of prostate cancer
  • 177 Lu-PSMA Radioligand Therapy for Prostate Cancer
    Abstract 177 Lu-prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) using inhibitors of PSMA is a novel therapeutic option in patients with metastatic castration-resistant prostate cancer The current literature suggests that this therapy is well tolerated and effective On the basis of clinical need and current evidence, the therapy is being implemented in a growing number of
  • PSMA-Targeted Therapy Is a Game Changer in Prostate Cancer Treatment . . .
    Dr Karine Tawagi Key Points: Lutetium-177-PSMA-617 (LuPSMA) is a prostate-specific membrane antigen (PSMA)–targeted radioligand therapy currently approved for patients with metastatic castration-resistant prostate cancer (mCRPC) following treatment with a prior androgen receptor signaling inhibitor (ARSI) and taxane chemotherapy
  • Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA . . .
    The objective of this study was to determine the safety, kinetics, and dosimetry of the 177 Lu-labeled prostate-specific membrane antigen (PSMA) small molecules 177 Lu-PSMA I T and 177 Lu-PSMA-617 in a large cohort of patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing PSMA radioligand therapy (PRLT) Methods: In total, 138 patients (mean age, 70 ± 9 y; age range
  • ASCO 2025: Lutetium-177-PSMA-617 in Oligo-Metastatic Hormone Sensitive . . .
    Overall, 14 56 (25%) of patients receiving 177 Lu-PSMA-617 had a complete biochemical response 9 56 (16%) had a PSA <0 1 ug L at data cut-off The adverse event profile was consistent with that of 177 Lu-PSMA-617 therapy The most common grade 1-2 adverse events were dry mouth, fatigue, nausea, and lymphopenia
  • [177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved . . .
    Abstract In March 2022, [177 Lu]Lu-PSMA-617 (Pluvicto TM) was approved by the FDA for the treatment of prostate cancer patients Until now, the approval has been limited to patients with PSMA-positive metastatic castration-resistant prostate cancer who have previously received other therapy options (such as inhibition of the androgen receptor pathway and taxane-based chemotherapy)
  • Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate . . .
    Background: Metastatic castration-resistant prostate cancer remains fatal despite recent advances Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic castration-resistant prostate cancer Lutetium-177 (177 Lu)-PSMA-617 is a radioligand therapy that delivers beta-particle radiation to PSMA-expressing cells and the surrounding microenvironment





中文字典-英文字典  2005-2009